Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients

The integration of additional biomarker assessments into MTB workflows enhances precision oncology by expanding the pool of patients eligible for targeted therapies.

Authors

Institutions

Publication Details

Journal
BMC Medicine
Published
2026-01-13
DOI
https://doi.org/10.1186/s12916-026-04636-y
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients

W Dietmaier, Daniel Heudobler, Anja Troeger, Anja M. Sedlmeier et al.
BMC Medicine
PARP inhibition in cancer therapy
article

Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients

W Dietmaier, Daniel Heudobler, Anja Troeger, Anja M. Sedlmeier, Hauke Christian Tews, Felix Steger, Marco J. Schnabel, Elisabeth Bumes, Kristina Wohlfart, Konstantin Drexler, B. Zwicker, Florian Lüke, Daniela Hirsch, Till Kaltofen, S. Haferkamp, Alexander Immel, Sabine Einhell, Kirsten Utpatel, Julia Maurer, Ulrich Kaiser, Christina Brummer, Frederik Hierl, Tobias Pukrop, Diego F. Calvisi, Sophie Schlosser-Hupf, Matthias Grube, Davor Lessel, S. A. Klemm, Stephan Seitz, Ramona Erber, Arne Kandulski, Felix Keil, Markus Perl, Elena Lüftl, Tom Schneider, Alexander Scheiter, Matthias Evert, Elena Wutzlhofer, Margit Klier-Richter, Christian Schulz, Simon Mellin, Johannes Meier
article en

Abstract

The integration of additional biomarker assessments into MTB workflows enhances precision oncology by expanding the pool of patients eligible for targeted therapies.

BMC MedicineVol. 24(1)
University Hospital Regensburg (DE), Fraunhofer Institute for Toxicology and Experimental Medicine (DE), Klinik Bavaria (DE), University of Regensburg (DE)
Good health and well-being
Openalex Percentile: Top 88%
PARP inhibition in cancer therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.